Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.52 per share in line with the Zacks Consensus Estimate. This compares to loss of$0.55 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this glaucoma treatments developer would post a loss of $0.58 per share when it actually produced a loss of$0.70, delivering a surprise of -20.69%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Glaukos, which belongs t ...